[The interferon therapy of patients with chronic viral hepatitis: the factors affecting the treatment results].
The paper presents clinicoimmunological characterization or therapeutic efficacy of alpha-interferons produced in Russia and criteria of their administration in patients with chronic viral hepatitis. A 6 to 12 months course (single dose 1 x 10(6)-3 x 10(6) IU improves the disease running, hepatic function and corrects immune status in 55.6% of patients with chronic active hepatitis eventuating in liver cirrhosis and in 57.9% of patients in chronic active hepatitis of moderate activity. Alpha-interferons are indicated in chronic active hepatitis and cirrhosis under high activity of cytolytic process, immunodeficiency, weak autoimmune process and protein shifts.
Kokoreva
L N
LN
Zmyzgova
A V
AV
Shalygina
N B
NB
D000293:Adolescent; D000328:Adult; D015551:Autoimmunity / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000276:immunology / Q000628:therapy*; D003699:Hepatitis D / Q000097:blood / Q000276:immunology / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000097:blood / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D016898:Interferon-alpha / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000097:blood / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged
D016898:Interferon-alpha
Interferonoterapiia bol'nykh khronicheskim virusnym gepatitom: faktory, vliiaiushchee na rezul'taty lecheniia.